Abstract: An electrocardiogram measurement system includes a patch-type electrocardiogram measurement apparatus, a first device connected to the electrocardiogram measurement apparatus by means of a first communication and configured to store electrocardiogram data measured by the electrocardiogram measurement apparatus, and a second device connected to the electrocardiogram measurement apparatus by means of the first communication and configured to store electrocardiogram data measured by the electrocardiogram measurement apparatus. The electrocardiogram data measured by the electrocardiogram measurement apparatus include measured time information. Other embodiments are disclosed.

Abstract: Aspects of the subject disclosure may include, for example, an apparatus for measuring an electrocardiogram signal and storing the electrocardiogram signal merged with a user input. The apparatus includes a signal detector, a signal converter, a motion sensor sensing movements of the apparatus for measuring electrocardiogram signal in x, y, and z-axis directions, an input unit receiving at least one type of the user input from among a voice input, a button input, and a touch input, a processor receiving the user input, and a mounting part being made of a flexible material and is implemented to be attached to a body of the object such that the apparatus is worn through the mounting part as a patch type. Other embodiments are disclosed.

Abstract: An atelocollagen according to an embodiment is characterized in that, when analyzed by high-performance liquid chromatography (HPLC), a peak area (S?) for a ? chain is larger than a second peak area for an ? chain (S?2) so that, when a physiologically active material is loaded therein, the atelocollagen may decrease rapid initial release of the physiologically active material or may control reduction in effects of the physiologically active material due to too slow initial release. Further, the atelocollagen of the present invention may exhibit excellent cancer metastasis inhibitory effects.

Abstract: One aspect according to the present disclosure relates to a novel nucleic acid ligand which is a new class of nucleic acid compound, the existence of which was considered impossible in the prior art. The novel nucleic acid ligand has specific binding affinity with respect to at least two different targets having three-dimensional structures, and the binding sites for the at least two targets are formed in or from a single nucleic acid ligand. The novel nucleic acid ligand according the present disclosure can simultaneously solve several problems of existing aptamers that the prior art could not solve. One aspect according to the present disclosure relates to a novel screening method for identifying the above-mentioned novel nucleic acid ligand. The novel screening method uses a step for sequentially contacting at least two different targets having three-dimensional structures to screen a novel nucleic acid ligand that was previously thought impossible.

Abstract: The present invention relates to an aptamer or a functional fragment thereof, capable of specifically binding to PD-L1 or capable of inhibiting interaction between PD-1 and PD-L1 by specifically binding to PD-L1, which includes a nucleic acid sequence of SEQ ID NO. 1, 2, 10 or 18.

Abstract: A composition for imaging a tumorous disease region includes a fluorescence- or radioactive isotope-labeled ERBB2 aptamer, wherein the ERBB2 aptamer labeled with a radioactive isotope or a fluorescent dye is used to image the tumorous disease region in vivo. The composition may include a labeled hybridized aptamer comprising an aptamer represented as formula 1 hybridized with a labeled-ODN represented as formula 2.

Abstract: An oligonucleotide variant according to an embodiment of the present disclosure has a structure of Formula 1 may exhibit excellent in-vivo stability and anticancer effects: (N)x-[TGG]m[TTG][TGG]n-(M)y??[Formula 1] wherein, N and M are independently deoxyuridine (dU), deoxycytidine (dC), uridine (U), or cytidine (C), in which a halogen or hydroxy group is bound to 5- or 2?-position thereof; x and y are independently integers of 0 to 10 (except when x and y are simultaneously 0), n is an integer of 1 to 10; and m is an integer of 1 to 10.

Abstract: A composition for imaging a tumorous disease region includes a fluorescence- or radioactive isotope-labeled ERBB2 aptamer, wherein the ERBB2 aptamer labeled with a radioactive isotope or a fluorescent dye is used to image the tumorous disease region in vivo. The composition may include a labeled hybridized aptamer comprising an aptamer represented as formula 1 hybridized with a labeled-ODN represented as formula 2.

Abstract: The present invention provides a novel class of peptide nucleic acid derivatives, which show good cell penetration and strong binding affinity for nucleic acid.

Abstract: The present invention provides a novel class of peptide nucleic acid derivatives, which show good cell penetration and strong binding affinity for nucleic acid.

Abstract: The present invention provides a novel class of peptide nucleic acid derivatives, which show good cell penetration and strong binding affinity for nucleic acid.

Abstract: The present invention provides a novel class of peptide nucleic acid derivatives, which show good cell penetration and strong binding affinity for nucleic acid.

Abstract: The present invention provides a novel class of peptide nucleic acid derivatives, which show good cell penetration and strong binding affinity for nucleic acid.

Abstract: The present invention provides a novel class of peptide nucleic acid derivatives, which show good cell penetration and strong binding affinity for nucleic acid.

Abstract: The present invention provides a novel class of peptide nucleic acid derivatives, which show good cell penetration and strong binding affinity for nucleic acid.

Abstract: The present invention provides a novel class of peptide nucleic acid derivatives, which show good cell penetration and strong binding affinity for nucleic acid.

Abstract: The present invention provides a novel class of peptide nucleic acid derivatives, which show good cell penetration and strong binding affinity for nucleic acid.